$ARTH
Arch Therapeutics, Inc. Stock $arth

$arth Overview Financials Valuation SEC Filings Company Website

2013 Form 10-K Financial Statement

#000114420413069281 Filed on December 27, 2013

Income Statement

Concept	2013	2012 Q3	2012
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.530M	$110.0K	$330.0K
YoY Change	363.64%	1000.0%	3200.0%
% of Gross Profit
Research & Development	$218.9K	$40.00K	$87.02K
YoY Change	151.55%
% of Gross Profit
Depreciation & Amortization	$586.00	$0.00	$3.372K
YoY Change	-82.62%
% of Gross Profit
Operating Expenses	$1.745M	$150.0K	$420.5K
YoY Change	314.95%	1400.0%	4105.24%
Operating Profit	-$1.745M		-$420.5K
YoY Change	314.95%
Interest Expense	$108.9K	-$40.00K	-$160.0K
YoY Change	-168.05%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00	$0.00
YoY Change
Pretax Income	-$1.850M	-$190.0K	-$580.0K
YoY Change	218.97%	1800.0%	5700.0%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.854M	-$190.0K	-$576.9K
YoY Change	221.33%	1800.0%	0.6%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.09		-$0.10
Diluted Earnings Per Share	-$86.57K	-$3.046K	-$9.340K
COMMON SHARES
Basic Shares Outstanding	21.37M shares		5.645M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013	2012 Q3	2012
SHORT-TERM ASSETS
Cash & Short-Term Investments	$560.0K	$20.00K	$20.00K
YoY Change	2700.0%		0.0%
Cash & Equivalents		$17.14K
Short-Term Investments
Other Short-Term Assets	$20.00K	$0.00	$0.00
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$1.580M	$20.45K	$20.00K
YoY Change	7800.0%		0.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$0.00	$908.00	$0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$10.00K	$0.00
YoY Change
Total Long-Term Assets	$10.00K	$908.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$1.580M	$20.45K	$20.00K
Total Long-Term Assets	$10.00K	$908.00	$0.00
Total Assets	$1.590M	$21.36K	$20.00K
YoY Change	7850.0%		0.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$310.0K	$258.4K	$260.0K
YoY Change	19.23%
Accrued Expenses	$140.0K	$352.8K	$520.0K
YoY Change	-73.08%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$280.0K	$280.0K
YoY Change	-100.0%
Long-Term Debt Due	$0.00	$1.500M	$1.500M
YoY Change	-100.0%
Total Short-Term Liabilities	$460.0K	$2.552M	$2.550M
YoY Change	-81.96%
LONG-TERM LIABILITIES
Long-Term Debt	$940.0K	$240.0K	$240.0K
YoY Change	291.67%
Other Long-Term Liabilities	$0.00	$10.00K	$10.00K
YoY Change	-100.0%
Total Long-Term Liabilities	$940.0K	$241.4K	$250.0K
YoY Change	276.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$460.0K	$2.552M	$2.550M
Total Long-Term Liabilities	$940.0K	$241.4K	$250.0K
Total Liabilities	$1.400M	$2.794M	$2.790M
YoY Change	-49.82%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock		$5.645K
YoY Change		41.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$190.0K	-$2.772M	-$2.770M
YoY Change
Total Liabilities & Shareholders Equity	$1.590M	$21.36K	$20.00K
YoY Change	7850.0%		0.0%

Cashflow Statement

Concept	2013	2012 Q3	2012
OPERATING ACTIVITIES
Net Income	-$1.854M	-$190.0K	-$576.9K
YoY Change	221.33%	1800.0%	0.6%
Depreciation, Depletion And Amortization	$586.00	$0.00	$3.372K
YoY Change	-82.62%
Cash From Operating Activities	-$1.435M	-$100.0K	-$254.6K
YoY Change	463.4%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.877M	100.0K	$235.0K
YoY Change	698.52%	400.0%	1075.0%
NET CHANGE
Cash From Operating Activities	-$1.435M	-100.0K	-$254.6K
Cash From Investing Activities	$0.00	0.000	$0.00
Cash From Financing Activities	$1.877M	100.0K	$235.0K
Net Change In Cash	$441.9K	-0.00000000002910	-$19.64K
YoY Change	-2350.42%	-100.0%	-198.18%
FREE CASH FLOW
Cash From Operating Activities	-$1.435M	-$100.0K	-$254.6K
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	-$1.435M	-$100.0K	-$254.6K
YoY Change	463.4%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
CY2012Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3308	USD
CY2012Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	908	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	55293	USD
CY2013	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	250000	USD
CY2012	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	235000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	235000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3886712	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	540180	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-19636	USD
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2013Q3	dei	Entity Public Float EntityPublicFloat	1979600	USD
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	60145237	shares
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	60145237	shares
CY2012Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5645212	shares
CY2012Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5645212	shares
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	557319	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17139	USD
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19629	USD
CY2013Q3	us-gaap	Notes Receivable Gross NotesReceivableGross	1000000	USD
CY2012Q3	us-gaap	Notes Receivable Gross NotesReceivableGross	0	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	1576948	USD
CY2012Q3	us-gaap	Assets Current AssetsCurrent	20447	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	322	USD
CY2012Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	908	USD
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10062	USD
CY2012Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2013Q3	us-gaap	Assets Assets	1587332	USD
CY2012Q3	us-gaap	Assets Assets	21355	USD
CY2012Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1395000	USD
CY2013Q3	arth	Convertible Notes Payable Related Parties Current ConvertibleNotesPayableRelatedPartiesCurrent	0	USD
CY2012Q3	arth	Convertible Notes Payable Related Parties Current ConvertibleNotesPayableRelatedPartiesCurrent	105000	USD
CY2013Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	0	USD
CY2012Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	275200	USD
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	314769	USD
CY2012Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	258426	USD
CY2013Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	140840	USD
CY2012Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	49510	USD
CY2013Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2012Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	116548	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	455609	USD
CY2012Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2552439	USD
CY2013Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	USD
CY2012Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	235000	USD
CY2013Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	944707	USD
CY2012Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
CY2013Q3	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	0	USD
CY2012Q3	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	6351	USD
CY2013Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	0	USD
CY2012Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	352755	USD
CY2013Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	944707	USD
CY2012Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	241351	USD
CY2013Q3	us-gaap	Liabilities Liabilities	1400316	USD
CY2012Q3	us-gaap	Liabilities Liabilities	2793790	USD
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	60145	USD
CY2012Q3	us-gaap	Common Stock Value CommonStockValue	5645	USD
CY2013Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4758742	USD
CY2012Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	0	USD
CY2013Q3	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	4631871	USD
CY2012Q3	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	2778080	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	187016	USD
CY2012Q3	us-gaap	Stockholders Equity StockholdersEquity	-2772435	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1587332	USD
CY2012Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21355	USD
CY2013Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	10384	USD
CY2013	us-gaap	Revenues Revenues	0	USD
CY2012	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	431461	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1526075	USD
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	333503	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3662040	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	218901	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	87021	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	866673	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	1744976	USD
CY2012	us-gaap	Operating Expenses OperatingExpenses	420524	USD
	us-gaap	Operating Expenses OperatingExpenses	4528713	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-420524	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4097252	USD
CY2013	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-108815	USD
CY2012	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-156387	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-1853791	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-576911	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4631871	USD
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21366752	shares
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5645212	shares
CY2006Q1	us-gaap	Stockholders Equity StockholdersEquity	0	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18153	USD
CY2007	us-gaap	Net Income Loss NetIncomeLoss	-450038	USD
CY2008	us-gaap	Net Income Loss NetIncomeLoss	-233040	USD
CY2009	us-gaap	Net Income Loss NetIncomeLoss	-504687	USD
CY2010	us-gaap	Net Income Loss NetIncomeLoss	-420093	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-573472	USD
CY2006Q3	us-gaap	Stockholders Equity StockholdersEquity	-18153	USD
CY2007Q3	us-gaap	Stockholders Equity StockholdersEquity	-464993	USD
CY2008Q3	us-gaap	Stockholders Equity StockholdersEquity	-698033	USD
CY2009Q3	us-gaap	Stockholders Equity StockholdersEquity	-1202527	USD
CY2010Q3	us-gaap	Stockholders Equity StockholdersEquity	-1622361	USD
CY2011Q3	us-gaap	Stockholders Equity StockholdersEquity	-2195524	USD
CY2007	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	3198	USD
CY2009	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1870	USD
CY2010	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	259	USD
CY2011	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	308	USD
CY2012	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2013	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1250000	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	750000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	287927	USD
CY2013	arth	Exchange Of Debt For Common Stock ExchangeOfDebtForCommonStock	2470022	USD
CY2013	us-gaap	Depreciation Depreciation	586	USD
CY2012	us-gaap	Depreciation Depreciation	3372	USD
	us-gaap	Depreciation Depreciation	18371	USD
CY2013	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-92	USD
	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	5752	USD
CY2013	arth	Noncash Interest Expense On Convertible Notes Payable NoncashInterestExpenseOnConvertibleNotesPayable	82147	USD
CY2012	arth	Noncash Interest Expense On Convertible Notes Payable NoncashInterestExpenseOnConvertibleNotesPayable	118657	USD
	arth	Noncash Interest Expense On Convertible Notes Payable NoncashInterestExpenseOnConvertibleNotesPayable	441253	USD
CY2013	arth	Noncash Interest Expense On Notes Payable To Related Party NoncashInterestExpenseOnNotesPayableToRelatedParty	25599	USD
CY2012	arth	Noncash Interest Expense On Notes Payable To Related Party NoncashInterestExpenseOnNotesPayableToRelatedParty	37211	USD
	arth	Noncash Interest Expense On Notes Payable To Related Party NoncashInterestExpenseOnNotesPayableToRelatedParty	142057	USD
CY2012	arth	Issuance Of Common Stock For Services IssuanceOfCommonStockForServices	1	USD
	arth	Issuance Of Common Stock For Services IssuanceOfCommonStockForServices	253	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	16321	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-648	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	19629	USD
CY2013	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	10062	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	10062	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	56343	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	139878	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	314769	USD
CY2013	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	91332	USD
CY2012	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	22508	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	140840	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1336332	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-254636	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3310340	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19053	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19053	USD
CY2013	arth	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	2000000	USD
	arth	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	2000000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1880000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1876512	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	557319	USD
CY2011Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36775	USD
CY2006Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	USD
CY2013	us-gaap	Interest Paid InterestPaid	98288	USD
CY2012	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Interest Paid InterestPaid	98288	USD
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2012	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2013	arth	Promissory Notes Receivable Debt With Warrants Issuance Costs Incurred During Non Cash Or Partial Non Cash Transaction PromissoryNotesReceivableDebtWithWarrantsIssuanceCostsIncurredDuringNonCashOrPartialNonCashTransaction	1000000	USD
CY2012	arth	Promissory Notes Receivable Debt With Warrants Issuance Costs Incurred During Non Cash Or Partial Non Cash Transaction PromissoryNotesReceivableDebtWithWarrantsIssuanceCostsIncurredDuringNonCashOrPartialNonCashTransaction	0	USD
	arth	Promissory Notes Receivable Debt With Warrants Issuance Costs Incurred During Non Cash Or Partial Non Cash Transaction PromissoryNotesReceivableDebtWithWarrantsIssuanceCostsIncurredDuringNonCashOrPartialNonCashTransaction	1000000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	287927	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	287927	USD
CY2013	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-373488	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	275200	USD
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-373488	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	275200	USD
CY2012	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	0	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	0	USD
CY2012	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2012	arth	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	USD
CY2012	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	0	USD
CY2013	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2012	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2013	arth	Issuance Of Common Stock For Services IssuanceOfCommonStockForServices	0	USD
CY2013	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
CY2012	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	105000	USD
CY2013	us-gaap	Use Of Estimates UseOfEstimates	<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 44pt" align="justify"><u><font style="FONT-SIZE: 10pt">Use of Estimates</font></u></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 44pt" align="justify"><font style="FONT-SIZE: 10pt">Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 44pt"> <u><font style="FONT-SIZE: 10pt">Concentration of Credit Risk</font></u></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 44pt"> <font style="FONT-SIZE: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash in bank deposits accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.</font></div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	105000	USD
CY2013Q3	arth	Convertible Preferred Stock Value Upon Closing Of Preferred Equity Financing ConvertiblePreferredStockValueUponClosingOfPreferredEquityFinancing	1000000	USD
CY2013	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	13062	USD
CY2013Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5991	USD
CY2012Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	19053	USD
CY2013Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets	5669	USD
CY2012Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets	18145	USD
CY2013Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	3486000	USD
CY2012Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	2228000	USD
CY2013Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	32559	USD
CY2012Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	32559	USD
CY2013Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2800000	USD
CY2012Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2120000	USD
CY2013	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	589213	USD
CY2012	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	198220	USD
CY2013Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1332955	USD
CY2012Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	884891	USD
CY2013Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	7492	USD
CY2012Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	7258	USD
CY2013Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	35744	USD
CY2012Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	10000	USD
CY2013Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1523921	USD
CY2012Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	934708	USD
CY2013Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1523921	USD
CY2012Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	934708	USD
CY2013Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2012Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2013Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	115171	USD
CY2012Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	0	USD
CY2013	arth	Percentage Of Principle Balance Of Notes On Conversion Price Of Notes PercentageOfPrincipleBalanceOfNotesOnConversionPriceOfNotes	0.2	pure
	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2010-08-10
CY2013	arth	Percentage Of Conversion Price Of Convertible Preferred Stock PercentageOfConversionPriceOfConvertiblePreferredStock	0.2	pure
CY2013Q1	arth	Convertible Notes Payable Related Parties Current ConvertibleNotesPayableRelatedPartiesCurrent	105000	USD
CY2010Q4	arth	Cash Bonus CashBonus	500000	USD
CY2010Q4	arth	Convertible Preferred Stock Value Upon Closing ConvertiblePreferredStockValueUponClosing	100000	USD
CY2010Q4	arth	Debt Instrument Convertible Threshold Amount DebtInstrumentConvertibleThresholdAmount	1000000	USD
CY2013Q2	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	14645237	shares
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1735000	USD
CY2013Q1	arth	Convertible Preferred Stock Value Upon Closing Of Preferred Equity Financing ConvertiblePreferredStockValueUponClosingOfPreferredEquityFinancing	1000000	USD
CY2011Q3	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	250000	USD
CY2011Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.06	pure
CY2011Q3	arth	Convertible Preferred Stock Value Upon Closing Of Preferred Equity Financing ConvertiblePreferredStockValueUponClosingOfPreferredEquityFinancing	750000	USD
CY2012Q3	arth	Matured Convertible Notes MaturedConvertibleNotes	1245000	USD
CY2012Q4	arth	Matured Convertible Notes MaturedConvertibleNotes	50000	USD
CY2013Q1	arth	Matured Convertible Notes MaturedConvertibleNotes	50000	USD
CY2013Q1	arth	Convertible Notes Payable Related Parties Current ConvertibleNotesPayableRelatedPartiesCurrent	1345000	USD
CY2013Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1880000	USD
CY2006Q4	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	3198105	shares
CY2009Q2	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	226290	shares
CY2009Q2	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	56596	shares
CY2009Q2	arth	Common Shares Attributable To Conversion Of Debt CommonSharesAttributableToConversionOfDebt	4000000	USD
CY2009Q2	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.04	pure
CY2009Q2	arth	Additional Stock Issued During Period Shares Issued AdditionalStockIssuedDuringPeriodSharesIssued	1468221	shares
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y
CY2013Q2	arth	Increase In Aggregate Number Of Shares IncreaseInAggregateNumberOfShares	3000000	shares
CY2013Q2	arth	Percentage Of Outstanding Number Of Shares PercentageOfOutstandingNumberOfShares	0.04	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7657	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.1188	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0088	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0240	pure
CY2013	arth	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate	0.00	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4825388	shares
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	288000	USD
CY2013	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M11D
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3000000	shares
CY2013	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3000000	shares
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	1500000	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3000000	shares
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.38
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.38
CY2013	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice	0.37
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	0.38
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y10M17D
CY2013	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedWeightedAverageRemainingContractualTerm	P0Y
CY2013	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm	P0Y
CY2013	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm	P0Y
CY2013	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm	P3Y10M24D
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y10M17D
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2013	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedAggregateIntrinsicValue	0	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2013	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodAggregateIntrinsicValue	0	USD
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2013	arth	Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodAggregateIntrinsicValue	0	USD
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	USD
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.0024
CY2011Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.0024
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.0024
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.0024
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.0024
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0.0024
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0
	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	42	shares
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1000000	USD
CY2013Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	2000000	USD
CY2013Q2	arth	Unit Issued Price Per Share UnitIssuedPricePerShare	0.50
CY2013Q2	arth	Proceeds From Investors In Contemplation Of Merger ProceedsFromInvestorsInContemplationOfMerger	1250000	USD
CY2013Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	0.75
CY2013Q3	us-gaap	Notes Payable NotesPayable	944707	USD
CY2009	arth	License Maintenance Costs LicenseMaintenanceCosts	10000	USD
CY2013	arth	License Maintenance Costs LicenseMaintenanceCosts	25000	USD
CY2010	arth	License Maintenance Costs LicenseMaintenanceCosts	10000	USD
CY2013Q3	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	35000	USD
CY2013Q3	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	45000	USD
CY2013Q3	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	50000	USD
CY2013Q3	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	50000	USD
CY2013Q3	us-gaap	Contractual Obligation ContractualObligation	180000	USD
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	60372	USD
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	30186	USD
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	90558	USD

Files In Submission

Name	View Source	Status
0001144204-13-069281-index-headers.html	Edgar Link	pending
0001144204-13-069281-index.html	Edgar Link	pending
0001144204-13-069281.txt	Edgar Link	pending
0001144204-13-069281-xbrl.zip	Edgar Link	pending
arth-20130930.xml	Edgar Link	completed
arth-20130930.xsd	Edgar Link	pending
arth-20130930_cal.xml	Edgar Link	unprocessable
arth-20130930_def.xml	Edgar Link	unprocessable
arth-20130930_lab.xml	Edgar Link	unprocessable
arth-20130930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v363048_10k.htm	Edgar Link	pending
v363048_ex31-1.htm	Edgar Link	pending
v363048_ex31-2.htm	Edgar Link	pending
v363048_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARTH
Arch Therapeutics, Inc. Stock $arth

2013 Form 10-K Financial Statement

#000114420413069281 Filed on December 27, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTH Arch Therapeutics, Inc. Stock $arth

2013 Form 10-K Financial Statement

#000114420413069281 Filed on December 27, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARTH
Arch Therapeutics, Inc. Stock $arth